Virax Biolabs Group Ltd (VRAX) stock
Close on Nov 12, 2026Market cap $386.74KP/E –Yield –
Virax Biolabs Group Ltd grew revenue 96.2% to $12.42K over fiscal 2026. Free cash flow was -$4.88M. At the latest close the market valued the company at $386.74K.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2026, balances at Mar 31, 2026
Valuation
- Market cap
- $386.74K
- P/E ratio
- –
- Price to sales
- 31.13
- Price to book
- 0.05
- Dividend yield
- –
- Free cash flow yield
- -1261.23%
Fundamentals
- Revenue
- $12.42K
- Net income
- -$5.02M
- EPS, diluted
- -$12.64
- Free cash flow
- -$4.88M
Trading
- Previous close
- $0.63
- Open
- $0.63
- Day's range
- $0.60 – $0.70
- Volume
- 84,704
- Average volume (20 days)
- 851,942
- Beta (5 years)
- 1.63
- 52-week range
- $0.50 – $21.75
- RSI (14 days)
- 20.6
- Volatility (1 year)
- 195.7%
- Relative volume
- 0.16×
- WACC
- 13.0%
Market cap history
Month-end market cap since 2022, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | VRAX | S&P 500 | Difference | VRAX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -63.9% | -2.7% | −61.2 pts | ||
| 3 months | -76.0% | -1.7% | −74.2 pts | ||
| Year to date | -92.3% | +11.9% | −104.2 pts | ||
| 1 year | -94.2% | +12.0% | −106.2 pts | ||
| 3 years | -99.0% | +78.2% | −177.2 pts | -78.3% | +21.2% |
Seven years at a glance
Fiscal years 2020 to 2026, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Virax Biolabs filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Virax Biolabs
In Vitro & In Vivo Diagnostic Substances
Virax Biolabs Group Limited is a biotechnology company specializing in immune response detection, T-cell immune profiling, and the development of in vitro diagnostic technologies for viral and immune-mediated conditions. The company centers its operations on two core platforms: ViraxImmune, an in-development diagnostic platform targeting post-acute infection syndromes like Long COVID, and ImmuneSelect, a research-use-only portfolio offering peptide pools, ELISpot plates, and related reagents. Its customer base includes academic institutions, research laboratories, contract research organizations, biopharmaceutical companies, independent laboratories, and commercial distributors.
Company profile, executives and historyVirax Biolabs stock: common questions
What is Virax Biolabs's stock price?
VRAX closed at $0.67 on Nov 12, 2026, up 6.47% on the day. Over the past 52 weeks it traded between $0.50 and $21.75.
What is Virax Biolabs's market cap?
Virax Biolabs was worth $386.74K at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is VRAX's P/E ratio?
Virax Biolabs lost money over fiscal 2026 (diluted EPS -$12.64), so it has no meaningful P/E ratio.
How much revenue does Virax Biolabs make?
Virax Biolabs reported revenue of $12.42K for fiscal 2026, up 96.2% from a year earlier.
Does Virax Biolabs pay a dividend?
No. Virax Biolabs has not paid a cash dividend over the last twelve months.
How has VRAX stock performed over the past year?
Including dividends, VRAX returned -94.2% over the past year, against +12.0% for the S&P 500.
How many VRAX shares are sold short?
0M shares were sold short at the latest FINRA report, 3.17% of the float, or 1.0 days of average trading volume.
Who are Virax Biolabs's competitors?
Companies most similar to Virax Biolabs by business, industry and size include CDIO, IFRX, GNLX, LYEL, PRFX.
See a number that looks wrong?